November 16, 2016 - By Dolores Ford · 0 Comments
The stock of Shire Plc Ads (NASDAQ:SHPG) registered a decrease of 4.62% in short interest. SHPG’s total short interest was 1.96 million shares in November as published by FINRA. Its down 4.62% from 2.05 million shares, reported previously. With 832,500 shares average volume, it will take short sellers 2 days to cover their SHPG’s short positions. The short interest to Shire Plc Ads’s float is 0.66%. The stock decreased 2.12% or $3.92 during the last trading session, hitting $181.04. Shire PLC (ADR) (NASDAQ:SHPG) has risen 0.29% since April 14, 2016 and is uptrending. It has underperformed by 4.39% the S&P500.
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The company has a market cap of $54.00 billion. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It has a 68.13 P/E ratio.
Out of 18 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 15 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 83% are positive. Shire plc (ADR) has been the topic of 28 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Thursday, August 6 by BNP Paribas. The company was upgraded on Monday, September 21 by Barclays Capital. The stock has “Hold” rating given by HSBC on Monday, September 26. The firm has “Sector Perform” rating given on Monday, September 28 by RBC Capital Markets. On Friday, May 20 the stock rating was maintained by JP Morgan with “Overweight”. Bank of America upgraded the stock to “Buy” rating in Monday, January 18 report. The firm has “Buy” rating given on Thursday, May 26 by Stifel Nicolaus. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, January 12. The rating was upgraded by Credit Suisse on Tuesday, January 12 to “Outperform”. The company was downgraded on Thursday, August 6 by Exane.
Shire plc, incorporated on January 28, 2008, is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.
More news for Shire PLC (ADR) (NASDAQ:SHPG) were recently published by: Marketwatch.com, which released: “Shire PLC ADR NASDAQ: SHPG” on July 12, 2012. Businessfinancenews.com‘s article titled: “Shire PLC (ADR) Future Now Rests On Xiidra” and published on July 12, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford